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The ability of bifidobacteria to adhere to the intestine of the human host is considered to be important for efficient colonization
and achieving probiotic effects. Bifidobacterium bifidum strains DSM20456 andMIMBb75 adhere well to the human intestinal
cell lines Caco-2 and HT-29. The surface lipoprotein BopA was previously described to be involved in mediating adherence of B.
bifidum to epithelial cells, but thioacylated, purified BopA inhibited the adhesion of B. bifidum to epithelial cells in competitive
adhesion assays only at very high concentrations, indicating an unspecific effect. In this study, the role of BopA in the adhesion
of B. bifidumwas readdressed. The gene encoding BopA was cloned and expressed without its lipobox and hydrophobic signal
peptide in Escherichia coli, and an antiserum against the recombinant BopA was produced. The antiserum was used to demon-
strate the abundant localization of BopA on the cell surface of B. bifidum.However, blocking of B. bifidum BopA with specific
antiserum did not reduce adhesion of bacteria to epithelial cell lines, arguing that BopA is not an adhesin. Also, adhesion of B.
bifidum to human colonic mucin and fibronectin was found to be BopA independent. The recombinant BopA bound only mod-
erately to human epithelial cells and colonic mucus, and it failed to bind to fibronectin. Thus, our results contrast the earlier
findings on the major role of BopA in adhesion, indicating that the strong adhesion of B. bifidum to epithelial cell lines is BopA
independent.
The adhesion of pathogenic and commensal bacteria to hostcells and tissues is considered an important step in the initia-
tion of disease and in mediating beneficial effects for the host,
respectively. In the gastrointestinal tract, adhesion is considered
an essential colonization factor for both commensal and probiotic
bacteria, and binding is known to be mediated by the surface pro-
teins and structures of both bacterial and host cells. Human com-
mensal and pathogenic bacteria may share some mechanisms of
adhesion, and thus commensal bacteria may protect against
pathogens by occupying adhesion sites (1, 2). The adhesionmech-
anisms of commensal and probiotic bacteria are currently under
intensive investigation; for example, the adhesion of probiotic
strain Lactobacillus rhamnosus GG was found to be mediated by a
pilus, a structure known to mediate the adhesion of many patho-
gens (2, 3). Furthermore, adhering commensals and probiotics
have close contact with the host epithelium and are proposed to
function in immune stimulation and gut maturation and to en-
hance epithelial integrity (2, 4, 5). Bifidobacteria are commensal
inhabitants of the human gastrointestinal tract, and they can con-
stitute a considerable part of an individual’s gut microbiota, espe-
cially in breast-fed infants (6, 7). Many Bifidobacterium species
and strains adhere strongly to human intestinal epithelial cells in
vitro (8, 9), but only a few adhesionmolecules have been described
thus far (9–11). The expression of moonlighting proteins on the
cell surface of Bifidobacterium seems to be common, and under
certain circumstances these proteins could facilitate colonization
of the human gut (12–14). Recently, moonlighting transaldolase
was reported to play a role in the autoaggregation and adhesion of
Bifidobacterium bifidum to mucin (10).
The proteins of tight adherence (Tad) pili have been shown to
be essential for the efficient gut colonization of Bifidobacterium
breve in vivo in mice, and a role for these proteins favoring the
adhesion of B. breve to the intestinal epithelium has been sug-
gested (11). Gene clusters responsible for the biosynthesis of pili
have been identified in the genomes ofB. bifidum (15). Recently, it
was demonstrated that the major subunit protein of the pil3 locus
of B. bifidum PRL2010, coding for the sortase-dependent pili, is
involved in the adhesion to Caco-2 cells and binding to extracel-
lular matrix (ECM) proteins (16). Pil3 seems to be partially, but
not solely, responsible for the adhesion of B. bifidum PRL2010 to
Caco-2 cells via ECM proteins and autoaggregation (16). The
same genetic locus has been found in all sequenced B. bifidum
strain genomes and also in the genome of the probiotic strain B.
bifidumMIMBb75 (S. Guglielmetti, unpublished data).
In B. bifidum, lipoprotein BopA (an outer surface lipoprotein)
was the first surface protein described to be involved in the adhe-
sion to intestinal epithelium. BopA purified from the cell wall of
the probiotic strain B. bifidumMIMBb75 partly inhibited the ad-
hesion of B. bifidum to Caco-2 cell line in a competitive adhesion
assay (9). However, the inhibition was successful only when BopA
was used at a remarkably high concentration, indicating that this
was a result of unspecific inhibition rather than a specific compe-
tition for the adhesion sites (9). Recently, Gleinser and colleagues
(17) expressed BopA in a poorly adherent strain, Bifidobacterium
longum subsp. infantisE18, and detected increased adhesion of the
strain (17). However, even with overexpression of BopA in the
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recipient strain, the adhesion was at a very low level compared
with that of the parental B. bifidum strain (source of the bopA
gene) (17), and therefore, the role of BopA as a true adhesin is still
questionable.
In this study, we readdressed the role of BopA in the adhesion
of B. bifidum. We cloned and expressed BopA without its hydro-
phobic signal sequence and lipobox (and therefore without the
thioacyl group) in Escherichia coli and produced an antiserum
against the recombinant BopA. The role of BopA in the adhesion
of B. bifidum to intestinal epithelium was reevaluated by using a
number of functional assays with the cell lines Caco-2 andHT-29,
four ECM proteins, and human intestinal mucus.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Bifidobacterium bifidum type
strain (DSM20456) and Bifidobacterium bifidumMIMBb75 (from the In-
dustrial Microbiology Culture Collection DiSTAM, University of Milan,
Milan, Italy) were cultivated in DeMan, Rogosa, and Sharpe broth (MRS;
Difco) supplemented with 500 g ml1 L-cysteine (Sigma-Aldrich) and
were incubated at 37°C in an anaerobic chamber.
Cloning, overproduction, and purification of recombinant BopA.
Chromosomal DNA of B. bifidum DSM20456 was extracted by using a
Wizard genomic DNA purification kit (Promega) according to the man-
ufacturer=s instructions after mechanical lysis of bacterial cells by bead
beating with zirconium beads (diameter, 0.1 mm) 3 times for 60 s each.
The bopA gene, without the regions encoding the signal sequence and
lipobox, was obtained by amplifying the chromosomal DNAof B. bifidum
DSM20456 with a primer pair, one containing the NcoI site (5=AATTAC
CATGGGCAACAACGGCGC3=) and another containing the HindIII site
(5=TAATTAAGCTTCTTCTCCCAGCCGAG3=) (designed on the basis of
the available bopA sequence of B. bifidumMIMBb75). The gene encoding
BopA was cloned into the vector pET28b (Novagen) for expression as a
C-terminal His6 fusion protein in E. coli strain BL21(DE3)(pLysS). The
BopA protein was purified from the cytoplasm of E. coli under native
conditions using the Qiaexpress protein purification system (Qiagen) ac-
cording to the manufacturer=s instructions.
Generation of the polyclonal anti-BopA antibodies. The immuniza-
tion protocol described by Johnston et al. (18) was used to raise polyclonal
rabbit antibodies against His6-BopA of B. bifidum DSM20456 (Labora-
toryAnimal Centre ofUniversity ofHelsinki). Briefly, a 1:1mixture of 400
ng of the purified recombinant His6-BopA and Freund=s complete adju-
vant was administered by subcutaneous injection. Preimmunization se-
rumwas collected before the primary immunization. The initial injection
was followed by 3 consecutive booster injections at 3-week intervals with
1:1 mixtures of 200 ng of the His6-BopA and Freund’s incomplete adju-
vant. Blood was collected 10 days after the last booster injection, and
antiserum was prepared according to standard protocols (19).
Subcellular localization of BopA. Immunogold-labeled thin sections
of B. bifidum DSM20456 and MIMBb75 were prepared for studying the
localization of BopA on the surface of B. bifidum strains by immunoelec-
tronmicroscopy (IEM) using anti-BopA antiserum or preimmune serum
as described previously (20). Briefly, bacteria were cultivated, washed, and
fixed prior to being embedded in Lowicryl HM20 resin. After polymeriza-
tion, ultrathin sections were cut and collected on carbon-coated nickel
grids. Sections were blocked (1% bovine serum albumin [BSA; Sigma-
Aldrich], 0.5% fish skin gelatin [FSG; Sigma-Aldrich], and 1% fetal calf
serum [FCS; IntegroBV] in sodiumphosphate buffer) and incubatedwith
anti-BopA antiserumor preimmune serum (both diluted 1:100 in sodium
phosphate buffer containing 2% BSA, 0.1% Tween 20, and 0.1% FSG) for
2.5 h at room temperature. Grids were then washed five times (0.2% BSA,
0.01% Tween 20, and 0.01% FSG in sodium phosphate buffer) and incu-
bated on drops of 1:80-diluted protein A conjugated to gold particles (10
nm) for 20 min. After extensive washing in phosphate buffer and distilled
water, the sections were poststained in uranyl acetate and lead citrate
before examination in a JEOL EXII transmission electron microscope.
The immunofluorescence stainingwas used to confirm the presence of
BopA on the surface of B. bifidum as detailed previously (21). Briefly, B.
bifidum cells were cultivated, washed with phosphate-buffered saline
(PBS), and fixedwith 3.5% (wt/vol) paraformaldehyde in PBS prior label-
ing with anti-BopA antiserum or preimmune serum as the primary anti-
serum and Alexa-488 (Invitrogen)-conjugated anti-rabbit IgG (1 g
ml1) as the secondary antibody. Bacteria were then examined with an
epifluorescence microscope (Leica DM 4000B) equipped with a filter for
the Alexa-488 label (excitation, 450 to 490 nm; emission, 515 nm), and
images were digitally recorded using CellPˆ imaging software for life sci-
ences microscopy (Soft Imaging System GmbH).
Isolation of cell envelope-associated proteins and the detection of
BopA in the cell envelope fraction. Cell wall-associated proteins of B.
bifidum strains DSM20456 and MIMBb75 were isolated as described by
Kankainen et al. (3). When the presence of BopA in the cell wall was
analyzed, the isolated proteins were separated in 12% (wt/vol) SDS-PAGE
and transferred onto 0.2-m Immobilon-P polyvinylidene difluoride
(PVDF)membranes (Millipore) forWestern blotting with anti-BopA an-
tiserum and horseradish peroxidase-conjugated anti-rabbit IgG (Bio-
Rad). The protein was then detected by using an enhanced chemilumi-
nescence (ECL) Advance Western blotting detection kit (Amersham)
according to the manufacturer=s instructions.
Caco-2 and HT-29 cell cultures. The human intestinal cell lines
Caco-2 andHT-29 were obtained fromDSMZ and were grown at 37°C in
a 95% air–5% CO2 atmosphere. Caco-2 cells were grown in RPMI 1640
medium (Sigma-Aldrich) supplementedwith 2mML-glutamine (Lonza),
20% heat-inactivated (30 min at 56°C) fetal calf serum, 100 U ml1 pen-
icillin-streptomycin (Lonza), and 1% (vol/vol) nonessential amino acids
(Lonza), and HT-29 cells were grown in McCoy 5A medium (Lonza)
supplemented with 10% fetal calf serum and 100 Uml1 penicillin-strep-
tomycin.
Isolation of human intestinal mucus. Human colonic mucus was
isolated from a healthy piece of tissue obtained from patients with colo-
rectal cancer. The mucus layer was collected as previously described (22).
In short, resected material was collected on ice within 20 min and pro-
cessed immediately by washing gently with PBS containing 0.01% gelatin.
The mucus was collected into a small amount of HEPES-Hanks buffer by
gently scraping with a rubber spatula, centrifuged (13,000  g, 10 min)
and stored at 20°C until further use. In the adhesion assays, mucus
preparations from several individuals were pooled in equal ratios, the
pooled mucus preparation was diluted to a protein concentration of 0.5
mgml1withHEPES-Hanks, and 100l of this solutionwas immobilized
passively onMaxisorpmicrotiter plate wells (Nunc) by overnight incuba-
tion at 4°C. The use of human intestinal mucus for the adhesion studies
was approved by the ethical committee of the Hospital District of South-
west Finland, and written informed consent was obtained from all pa-
tients from whom mucus was collected.
Bacterial adhesion to Caco-2 and HT-29 cells, isolated human mu-
cus, and ECM proteins. For the adhesion tests Caco-2 and HT-29 cells
were cultivated on 96-well tissue culture plate (10,000 cells well1; Nunc)
for 3, 8, and 21 days. The cells were washed twice with culture medium
before the adhesion assay. Laminin (Sigma-Aldrich), collagen I (Sigma-
Aldrich), collagen IV (Sigma-Aldrich), fibronectin (Calbiochem), fetuin
(Sigma-Aldrich), and BSA (Sigma-Aldrich) were immobilized on Max-
isorpmicrotiter wells at a concentration of 2.5 pmolwell1 (23). Thewells
containing immobilized mucus or ECM proteins were washed twice with
PBS and incubated with blocking buffer (0.5% [wt/vol] BSA in PBS) for 1
h at room temperature. The wells were washed again three times with PBS
prior to the addition of bacteria. B. bifidum DSM20456 and MIMBb75
were metabolically radiolabeled by cultivating bacteria with 10 l ml1
[5=-3H]thymidine (17.0 Ci/mmol; PerkinElmer). The adhesion assay was
performed as described previously by Vesterlund et al. (22) with the fol-
lowingmodifications. After cultivation, bacteria were collected by centrif-
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ugation and washed with RPMI 1640 without supplements (adhesion to
Caco-2 cells), McCoy 5Awithout supplements (adhesion to HT-29 cells),
or PBS (adhesion to mucus and ECM proteins). The optical density was
adjusted (A600  0.25) to the same culture medium or buffer used for
washing. Bacteria (100 l) were incubated on mucus or ECM proteins at
37°C or on the epithelial cells in a CO2 incubator at 37°C for 1 h, and the
nonadherent bacteria were removed by washing the wells three times with
PBS. Bacteria bound to cells, mucus, or ECMproteins were lysed with 1%
SDS–0.1 M NaOH by incubating at 60°C for 1 h. The radioactivity of the
suspension wasmeasured by liquid scintillation. Four to five parallel wells
(i.e., technical replicates) were used in each experiment, and all experi-
ments were repeated two to seven times. The percent bacterial adhesion
was determined by calculating the ratio between the radioactivity of the
adherent bacteria and that of the added bacteria. In the inhibition assays,
bacteria were preincubated with anti-BopA antiserum or preimmune se-
rum diluted 1:100 in culture medium or PBS prior to addition of bacteria
to the cells, mucus, or ECM proteins. In competition assays, Caco-2 and
HT-29 cells were incubated with His6-BopA (100 g well
1) in a CO2
incubator at 37°C for 1 h prior to the adhesion assay with bacteria.
Binding of 125I-BopA to epithelial cells, mucus, and ECM proteins.
Recombinant BopA was radiolabeled (125I), and the binding assays to
mucus and ECM proteins were performed essentially as detailed by
Kankainen et al. (3). Mucus and ECM proteins were immobilized on
Maxisorp microtiter wells and blocked with BSA as described above.
Caco-2 andHT-29 cells were cultivated on 96-well microtiter plates for 3,
8, and 21 days and washed twice with culture medium without supple-
ments. The 125I-labeled BopA (50 pmol) was added to the wells and incu-
bated for 1 h at 37°C in aCO2 incubator. Thewells were thenwashed three
times with PBS to remove any loosely bound protein, treated with 1%
SDS–0.1 M NaOH, and incubated at 60°C for 1 h. The radioactivity of
bound 125I-BopA was measured in a Wallac 1480 Wizard-3 automatic
gamma counter. Four to six parallel wells (i.e., technical replicates) were
used in each protein binding experiment, and all experiments were re-
peated two to four times.
Statistical analysis. A pairwise Student=s t test was used to determine
the significant difference (P  0.05) between the samples and controls.
Results shown in Fig. 3, 4, and 5 are the means standard deviations for
technical replicates (parallel wells) from representative experiments.
RESULTS
Purification of BopA and production of specific antiserum. The
gene coding for B. bifidum DSM20456 lipoprotein BopA missing
the signal sequence and lipobox (i.e., the recognition signal for
lipidmodification by thioacylation)was cloned into an expression
vector. The bopA sequence of B. bifidum MIMBb75 was available
from the previous studies (9), and it was utilized in designing the
primers used for the amplification of bopA gene of B. bifidum
DSM20456. The gene was then sequenced, and the obtained DNA
sequencewas identical to that of bopA ofB. bifidumMIMBb75 (9).
The BopA was expressed as a His6 fusion in E. coli under native
conditions and purified by nickel-nitrilotriacetic acid (Ni-NTA)
affinity chromatography. The purified protein was analyzed by
SDS-PAGE and Western blotting (Fig. 1). The fusion protein
showed an expected apparent molecular size of 61 kDa (Fig. 1A),
and no other peptides were detected in the SDS-PAGE, indicating
a high purity of the protein. Next, antiserum against His6-BopA
was produced, and its reactivity was tested by Western blotting.
The hyperimmune serum against BopA reacted well with the re-
combinant protein (Fig. 1B), whereas the preimmune serum
failed to recognize it (Fig. 1B).
Cellular location of BopA. Three different methods were used
to study the cellular localization of BopA in B. bifidumDSM20456
and MIMBb75. First, BopA was visualized in thin-sectioned B.
bifidum cells by IEM using antiserum produced against His6-
BopA in a combination with the protein A conjugated to 10-nm
gold particles. IEM revealed that themajority of BopA is within or
in close proximity to the cell wall, whereas preimmune serum
failed to detect BopA in the thin sections (Fig. 2A). Second, the
surface localization of BopA was verified in B. bifidumDSM20456
and MIMBb75 cells by indirect immunofluorescence staining
(Fig. 2B). BopA was present on the cell surfaces of both strains
(Fig. 2B), but the staining was not evenly distributed around the
cells, suggesting a localized distribution of BopA on the cell sur-
face. The preimmune serum did not give any signal with B. bifi-
dum cells in immunofluorescent staining (Fig. 2B). Third, the cell
envelopes were extracted from B. bifidum DSM20456 as well as
MIMBb75, and BopA was detected among the cell surface-associ-
ated proteins byWestern blotting using the anti-BopA antiserum.
The antiserum recognized the native, cell envelope-associated
BopA, and the amount of BopA in the cell surface extracts was
found to be comparable in the two strains (Fig. 2C). In conclusion,
BopA was shown to be abundantly present in the cell envelopes of
both studied strains of B. bifidum.
Role of BopA in B. bifidum adhesion to epithelial cell lines.
The adherence of B. bifidum DSM20456 and MIMBb75 as well as
the binding of recombinant BopA protein to the epithelial cells of
different ages was tested. Caco-2 cells differentiate in 14 days after
confluence, and the adhesion and binding properties were tested
with undifferentiated cells (3 days) in addition to cells at two dif-
ferentiation stages (8 and 21 days). The number of added cells
(10,000 cells well1) resulted in confluence in 3 days; i.e., at all
growth times, the cell cultures were confluent. For comparison,
the same growth times were used for HT-29 cell line. Both strains,
B. bifidum DSM20456 and MIMBb75, were found to adhere well
to Caco-2 andHT-29 cells. The adhesion wasmost efficient (12 to
23%) with 8-day-old epithelial cells and the weakest (5 to 11%)
with 21-day-old cells (Fig. 3A). The binding of 125I-labeled His6-
BopA to 3- and 8-day-old Caco-2 and 8- and 21-day-old HT-29
cells was found to be statistically significantly (P  0.05) higher
than the background level binding of 125I-BSA (Fig. 3B).However,
FIG 1 Purified recombinant BopA protein without the signal peptide and
lipobox motif. SDS-PAGE (A) and Western blotting (B) analysis of purified
His6-BopAwere carried out. TheWestern blotting detection of 5 ng of purified
His6-BopA was done by using anti-BopA antiserum. The reactivity of preim-
mune serum is shown as a control. The molecular masses (in kDa) of the
standard proteins are indicated on the left.
BopA-Independent Adhesion of Biﬁdobacterium biﬁdum
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the moderate level of His6-BopA binding (maximum, 2.5 times
greater than the background binding level of BSA) and the rela-
tively high adhesion (up to 23% adherence) of B. bifidum to the
epithelial cells indicated that BopA may not have a major role in
mediating bifidobacterial adhesion to Caco-2 andHT-29 cells. To
readdress the role of BopA as an adhesin, we tested the inhibition
of bacterial adhesion to epithelial cell lines in the presence of anti-
BopA antiserum, preimmune serum, and purified His6-BopA. In
the inhibition assays, where bacterial cells were pretreatedwith the
antiserum (diluted 1:100) prior to addition of bacteria to the cells,
no significant reduction in the bacterial adherence was observed
(Fig. 3A). As an exception, the adherence of B. bifidumMIMBb75
to 3-day-old Caco-2 cells was significantly diminished upon pre-
treatment with anti-BopA antiserum. However, the preimmune
serum also inhibited adhesion, indicating a BopA-independent
inhibitory effect of the antiserum in the binding assay (Fig. 3A).
The results were not affected when the serum was used at higher
concentrations (diluted 1:50 and 1:10) (data not shown). In the
competition assays, the epithelial cells were first incubatedwith an
extremely large amount (1 mg ml1) of recombinant BopA prior
to the bacterial adherence. Similarly to the inhibition assays, no
significant reduction was observed in the adherence of B. bifidum
to epithelial cells of different ages in the competition assay, with
the exception of the diminished adherence ofMIMBb75 to 3-day-
old Caco-2 cells in the competition with His6-BopA (Fig. 3A). A
slight variation in the adhesion levels as well as in the inhibition of
the adhesion with the addition of anti-BopA antiserum or His6-
BopA was seen between the experiments. Figure 3 shows that B.
bifidumDSM20456 and MIMBb75 are highly adherent to epithe-
lial cells (5 to 25% of added bacteria adhered) and that in general
the adhesion could not be inhibited with the pretreatment of bac-
terial cells by anti-BopA antiserum or outcompeted with the ad-
dition of recombinant BopA protein.
Role of BopA in B. bifidum adhesion to mucus. B. bifidum
strains DSM20456 and MIMBb75 were found to be adherent to
mucus (Fig. 4A), and the recombinant His6-BopA was found to
bind moderately to human colonic mucus (Fig. 4B). To study the
role of BopA inmediating the adhesion ofB. bifidum tomucus, the
anti-BopA antiserum was used to inhibit the bacterial adhesion,
and preimmune serum was used as a control. A minor decrease
was seen in the adhesion when bacterial cells were pretreated with
the anti-BopA antiserum, but the decrease was not statistically
significant. These results suggest that BopA has only a minor role,
if any, in the adherence of B. bifidum to human colonic mucus.
Role of BopA in B. bifidum adhesion to ECM proteins. The
adherence of B. bifidum DSM20456 and MIMBb75 cells and the
binding of His6-BopA to ECM proteins laminin, collagen I, colla-
gen IV, fibronectin, and fetuin (highly glycosylated protein) were
studied. Both strains of B. bifidum showed adhesiveness to fi-
bronectin, and B. bifidumMIMBb75 also adhered to laminin (Fig.
5A). Based on these results, we selected laminin and fibronectin
for the inhibition experiments. The bacteria were incubated with
anti-BopA antiserum or preimmune serum before being added to
the immobilized ECM proteins. Significant inhibition in the ad-
hesion of both strains of B. bifidum to fibronectin was detected
(Fig. 5B andC), whereas antiserumdid not affect the adherence to
laminin (Fig. 5C). However, since the preimmune serum caused a
similar reduction in bacterial adhesion, these results suggest an
unspecific effect, rather than a specific BopA-dependent inhibi-
tion, brought about by the anti-BopA antiserum. This was further
supported by the results of His6-BopA binding to ECM proteins,
as recombinant BopA showed moderate binding to laminin,
whereas it failed to bind fibronectin (Fig. 5D).
DISCUSSION
Commensal intestinal bacteria in the genus Bifidobacterium are
thought to balance the intestinal microbiota and to exert health-
promoting effects on the host (24–26), and some strains are also
used as probiotics. Adhesion of probiotic and commensal bacteria
to the intestinal epithelial cells, mucus, and ECM proteins could
help these organisms to persist in the intestinal tract and enable
close contact with the host. In healthy individuals, the gastroin-
FIG 2 Subcellular localization of BopA in B. bifidum DSM20456 and MIMBb75. (A) Immunoelectron microscopy images of the localization of BopA in B.
bifidum cells. Detection was done on thin sections by using anti-BopA (hyperimmune serum) and protein A-gold particles (pAp). The arrows indicate the pAp
binding to the cell surface. Preimmune serum labeling of cells was used as a negative control. Bar, 200 nm. (B) Immunofluorescence staining of B. bifidum
DSM20456 and MIMBb75 cells with anti-BopA and Alexa-488-conjugated secondary IgG. Preimmune serum was used as a negative control. Phase-contrast
images of the same microscopic fields are shown on the right. (C) Western blotting of BopA in the cell wall extracts of B. bifidum DSM20456 and MIMBb75.
His6-BopA (5 ng) is shown for comparison.
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testinal epithelium is covered with mucus, which forms a thick,
continuous layer in the large intestine. However, in the small in-
testine, the mucus layer is thinner and discontinuous, allowing
direct contact between epithelial cells and luminal bacteria. Also,
under certain conditions, the mucus barrier is reduced, and bac-
teria can penetrate the layer and adhere to the underlying epithe-
lial cells and ECM proteins (27).
The bifidobacterial lipoprotein BopA, which has homology
with the solute-binding protein of the ABC transport system in
Gram-positive bacteria, has been described as an adhesive surface
protein of B. bifidum MIMBb75 (9). The previous studies of the
localization of BopA on the cell surface as well as its role in the
adhesion were performed with a native BopA purified from the
cell envelope of B. bifidum (9). In the present study, the role of
BopA as a bifidobacterial adhesion molecule was readdressed by
exploiting antiserum against His6-BopA and by using a recombi-
nant BopA without the membrane-spanning lipid moiety cova-
lently linked to the cysteine residue in the lipobox and thus avoid-
ing possible unspecific effects resulting from the hydrophobic
nature of the N-terminal part of the native protein. The recombi-
nant BopA was produced with a C-terminal His6 tag, and it could
not be ruled out that it had the same conformation as the native
FIG 3 Adhesion ofB. bifidum (A) and binding ofHis6-BopA (B) to 3-, 8-, and 21-day-old epithelial cells. (A) Adhesion (%) of
3H-labeledB. bifidumDSM205456
and MIMBb75 to Caco-2 and HT-29. Anti-BopA and His6-BopA were used in the inhibition and competition assays, respectively, to assess the role of BopA in
adhesion. Preimmune serumwas used as a negative control. The results of 5 technical replicates (parallel wells) from the representative experiments are expressed
as means standard deviations. Significant reductions (P 0.05) in the adhesion in the inhibition/competition assays compared to the basic adhesion assay are
indicated with asterisks. (B) Binding of 125I-labeled BopA and 125I-BSA (negative control) to Caco-2 andHT-29. Results are themeans standard deviations for
four to six technical replicates (parallel wells) of the representative experiments. Binding significantly above that of the negative control (125I-BSA) is indicated
with an asterisk.
BopA-Independent Adhesion of Biﬁdobacterium biﬁdum
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protein; consequently, the recombinant protein may have had al-
tered binding properties compared to the native one. However,
the antiserum raised against the recombinant protein also recog-
nized the native BopA, and therefore, both His6-BopA and the
antiserum were considered suitable for the subsequent experi-
ments.
By using the antiserum, it was evident that BopA is an abun-
dantly expressed surface protein of B. bifidum. It was found to be
localized unevenly on the cell surface rather than being distributed
uniformly around the cells. Asymmetric localization of the surface
proteins, including the proteins involved in transporting of sub-
strates across the cytoplasmic membrane, was described earlier
and seems to be a commonmechanism in Gram-positive bacteria
(28, 29). It has been speculated that the cell wall passage of pro-
teins is restricted to a limited number of sites to maintain the cell
wall rigidity and withstand the turgor pressure (28). Alternatively,
the cell surface of B. bifidum is covered with an uneven layer of
exopolysaccharides, which results in an uneven staining and con-
sequently gives an image of patchy localization of BopA on the cell
surface.
The human intestinal isolateB. bifidumMIMBb75 and the type
strain ofB. bifidum, DSM20456, display an adhesive phenotype on
the epithelial cell lines Caco-2 andHT-29 depending on the age of
the epithelial cell culture. The differentiation stage of the epithelial
cells affects the expression of surface molecules (30, 31), which
affects the bacterial adhesion to the cells (32). In accordance, our
results show various levels of adhesion to the epithelial cells of
different ages or at different stages of differentiation. Only mini-
mal effects or no effect at all were caused by the BopA-specific
antiserum (inhibitory experiments) or the recombinant His6-
BopA (competitive experiments) on the adhesion of B. bifidum
DSM20456 and MIMBb75 to Caco-2 or HT-29 cells. Further-
more, a reduction in the adhesion of B. bifidum MIMBb75 to the
3-day-old, nondifferentiated Caco-2 cells was observedwhen bac-
teria were pretreated with the anti-BopA antiserum, but also, the
preimmune serum inhibited the adhesion, indicating a non-
BopA-based inhibition effect of the antisera.
In the competitive adhesion assays, only a moderate 28% re-
duction in the binding of B. bifidum MIMBb75, but not
DSM20456, to the 3-day-old Caco-2 cells was observed when the
epithelial cells were pretreated with the recombinant His6-BopA,
suggesting that BopA may be a minor accessory adhesin. His6-
BopA did not inhibit the adhesion of B. bifidum MIMBb75 to
HT-29 or to older Caco-2 cells.
FIG 4 Adhesion of B. bifidum and binding of His6-BopA to colonic mucus.
(A) Adhesion (%) of 3H-labeled B. bifidum DSM20456 and MIMBb75 to co-
lonic mucus was measured. In the inhibition assays, bacteria were pretreated
with anti-BopA antiserum or preimmune serum before adhesion. (B) Binding
of 125I-labeled BopA and 125I-labeled BSA (negative control) to immobilized
human colonicmucus. Results are themeans standard deviations of five (A)
or six (B) technical replicates (parallel wells) of the representative experiments.
Binding significantly above that of the negative control (125I-BSA) is indicated
with an asterisk (P 0.05).
FIG 5 Adhesion of B. bifidum and binding of His6-BopA to extracellular
matrix (ECM) proteins. (A) Adhesion (%) of radiolabeled (3H) B. bifidum
DSM20456 and MIMBb75 to immobilized ECM proteins and BSA (back-
ground level of adherence). Adhesion significantly above the background level
is indicated with an asterisk (P 0.05). (B and C) Inhibition of adhesion with
anti-BopA antiserum and preimmune serum treatment of ECM proteins.
ECM proteins to which adhesion was above the background level were in-
cluded in the inhibition assays. B. bifidum DSM20456 (B) and B. bifidum
MIMBb75 (C) were pretreated with anti-BopA antiserum (gray columns) or
preimmune serum (white columns) or left untreated (black columns) before
adhesion. Significant reduction (P  0.05) in the adhesion in the inhibition
assays compared to the basic adhesion assay is indicated with an asterisk. (D)
Binding of 125I-labeled BopA to ECM proteins and BSA (background level of
binding). Binding significantly above the background level is indicatedwith an
asterisk (P 0.05). Results are themeans standard deviations of four (A and
D) or three (B and C) technical replicates (parallel wells) of the representative
experiments.
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The previous reports on the role of BopA as an adhesin for
Caco-2 cells were based on competitive binding experiments done
with remarkably high concentrations (375mgml1) of BopA con-
taining the hydrophobic lipid moiety, which likely consists of a
diglyceride molecule covalently linked to the N-terminal cysteine
of BopA (9). In a more recent study, Gleinser and colleagues (17)
observed a reduction in the adhesion of B. bifidum when the epi-
thelial cells were pretreated with a recombinant His6-BopA pro-
tein, which was prepared by cloning the complete bopA gene. It
includes a DNA sequence coding for an N-terminal hydrophobic
signal peptide of 25 amino acids, which meets all of the require-
ments for a transmembrane helix, and contains the lipobox motif
(17). In this study, no inhibitory effect on the bifidobacterial bind-
ing to the epithelial cells could be confirmed by using a recombi-
nant His6-BopA devoid of the membrane-spanning lipid moiety
and the 25-amino-acid hydrophobic signal sequence, or by block-
ing the bifidobacteria with the BopA-specific antiserum. The in-
hibition observed in the previous studymay have resulted from an
unspecific effect caused by the higher hydrophobicity of the BopA
(lipo)proteins used in the study. Accordingly, the surface layer
(S-layer) proteins of Lactobacillus, which are rich in hydrophobic
amino acids (33), have been shown to inhibit the adhesion of S.
aureus to Caco-2 cells (34). Furthermore, it has been shown that
cell surface hydrophobicity indicates good adhesion potential for
bacteria and that the high hydrophobicity of the cell surface of a
probiotic strain correlates well with its capacity to inhibit patho-
gen adhesion through steric hindrance (35). In other words, it
seems that hydrophobicmolecules bind efficiently to the epithelial
cells and thereby block the bacterial binding sites by steric hin-
drance. Similarly, the competitive inhibition of bifidobacterial ad-
hesion to the epithelial cells caused by a lipid- or signal peptide-
containing hydrophobic BopA could have resulted from a steric
hindrance to the adhesion sites following an aspecific hydropho-
bic interaction of BopA protein with Caco-2 cell surface.
Recently, Gleinser and colleagues (17) also used bifidobacteria
overexpressing BopA to address its role as an adhesin. The over-
expression of BopA in B. longum subsp. infantis E18, a strain that
does not contain the gene coding for BopA and shows only a very
weak adhesion to the epithelial cells, increased the adhesion of the
strain to T84, Caco-2, and HT-29 cells by 511, 180, and 209%,
respectively (17). However, the adhesion of E18 to Caco-2 was
below 3%, and adhesion toT84 andHT-29was even lower. There-
fore, a 180% rise in the relative binding of the recombinant B.
longum subsp. infantis E18 to Caco-2 cells would mean an abso-
lute adhesion level of 5.4% (17), which is still far from the ad-
herence of the wild-type-BopA-bearing B. bifidum strains, which
show adherence above 30%. Thus, the increase in the adhesion
obtained by overexpressing bopA does not explain the high adher-
ence of wild-type B. bifidum observed here and by others (9, 17).
The slight increase in the adhesion ofB. longum subsp. infantisE18
overexpressing bopA indicates, however, that BopAmay serve as a
minor adhesin (17).
In healthy individuals, the gastrointestinal tract is covered by
two layers of mucus. The inner layer is firmly attached to the
epithelium, and the outer layer is more loosely attached and col-
onized by bacteria (36–38). B. bifidumDSM20456 andMIMBb75
showed approximately 4 and 8% adhesion to human colonic mu-
cus, respectively, whereas the recombinant His6-BopA bound
moderately to mucus. However, the antiserum produced against
His6-BopA failed to decrease the adhesion of B. bifidum tomucus,
indicating that BopA is not the major adhesin mediating the
bifidobacterial adherence to mucus either. Previously, both
DSM20456 and MIMBb75 were found to adhere to immobilized,
commercially available mucus, and the surface-exposed proteins
have been suggested to be involved in the binding (10, 39).
Transaldolase was reported to mediate the autoaggregation of the
bifidobacterial cells at acidic pH, which was linked to the mucus-
binding capacity of B. bifidum (10). However, as the autoaggre-
gating phenotype of B. bifidum is strictly dependent on acidic pH
(39), and since in this study all binding experiments were per-
formed at neutral pH and autoaggregation was not observed,
autoaggregation cannot explain the strong adhesion of B. bifidum
to mucus at neutral pH. The recombinant His6-BopA bound,
though moderately, to mucus, and therefore, it seems that BopA
may serve as a minor moonlighting adhesin. It has been suggested
that specific ABC transporter proteins are involved in host-bacte-
rium interactions and act as moonlighting adhesins (40–43), par-
ticularly in mucus binding (40, 43). Similarly, BopA may serve as
aminormoonlighting adhesinmediating bifidobacterial adhesion
to mucus at neutral pH.
Next, the binding of His6-BopA and adherence of B. bifidum to
ECM proteins was studied. The ECM is known to serve as a sub-
strate for the attachment of colonizing microorganisms (44).
ECM is a highly structured network of four main components,
collagens, laminin, fibronectin, and elastin (45). Both B. bifidum
strains studied adhered to fibronectin, and B. bifidum MIMBb75
adhered to laminin, but adherence to collagen I or IV was not
observed. The adhesion to fibronectin was inhibited when bacte-
rial cells were pretreated with anti-BopA antiserum but also when
they were pretreated with preimmune serum, again suggesting an
unspecific inhibitory effect of the antisera. The inhibitory effect of
the antisera on the bacterial adhesion to fibronectin could have
resulted from (i) the binding of antisera directly to the immobi-
lized fibronectin or (ii) the serum itself containing fibronectin,
which binds to fibronectin receptors on the bacterial surface. Sim-
ilarly, the inhibitory effect of antisera on the adhesion of B. bifi-
dumMIMBb75 to 3-day-old Caco-2 cells may have resulted from
antiserum binding to fibronectin, which can be produced by
Caco-2 cells (46). The recombinant BopA, however, did not bind
to fibronectin and excluded the role of BopA in mediating the
bifidobacterial adhesion to fibronectin. Instead of fibronectin, the
recombinant BopA bound to laminin, indicating that BopA may
act as a minor adhesin to ECM.
In conclusion, our results show, in contrast to previous studies,
that BopA has a very limited role in adhesion and that the adher-
ence of B. bifidum to epithelial cells, mucus, or ECM proteins is
BopA independent. However, BopA binds moderately to human
colonicmucus and laminin andmay act as aminor coadhesin ofB.
bifidum. Very recently, pil3 sortase-dependent pili were shown to
be involved in the adhesion of B. bifidum (16). Further studies are
needed to unambiguously demonstrate whether these pili or other
bacterial structures are the main adhesion molecules mediating
the adhesion of B. bifidum to epithelial cells.
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